专门生产植绒拭子的制造商 & CHG产品.

获取报价

» 公司新闻 » What obstacles should be cleared before the full vaccination in COVID-19

在全面接种 COVID-19 疫苗之前应清除哪些障碍

2020-12-04

全球医学界正在以前所未有的速度和规模开发Covid-19疫苗, 而且，各个国家的政府对疫苗被释放并使用疫苗有很大的期望. 最近, 世界上正在开发的几种疫苗经常被报道. 上个月, 几种著名的疫苗宣布了III期临床试验的有效性; 十二月 2, the British government approved the use of COVID-19 vaccine developed by Pfizer and German biotechnology companies; Mardner also announced that it will test COVID-19 vaccine on children … Despite this, Nature pointed out in the report that this does not mean that the vaccine will be fully vaccinated soon. Before that, solving the problems of vaccine hesitation, supply logistics, distribution, pricing and payment will help clear the obstacles.

Pfizer Pharmaceuticals Co., 有限责任公司. announced on November 9 that the COVID-19 vaccine developed by Pfizer in cooperation with German Biotechnology Company was more than 90% effective in Phase III clinical trials. The Independent reported on November 26th that American pharmaceutical company Mardner announced that the candidate COVID-19 vaccine developed by them was more than 90% 有效的. 此外, Oxford University and AstraZeneca Company also claimed that the average curative effect of a candidate COVID-19 vaccine developed by them was 70.4%. Early studies have shown that these candidate vaccines can stimulate the immune response. The latest experiment proves that this immune response can protect people from COVID-19.

On December 2nd, the British government announced that its Medicines and Health Products Administration (MHRA) had approved the use of COVID-19 vaccine developed by Pfizer and German biotechnology companies, which will be launched in Britain from next week. This urgent authorization cleared the way for vaccine deployment in Britain! On November 30th, 当地时间, American Mardner Company applied to the US Food and Drug Administration (食品药品监督管理局) for emergency use of its candidate vaccine, saying that its vaccine was effective and there was no “serious safety problem” during the trial. According to a report in the Capitol Hill Daily on the 2nd, Mardner Company said that it would recruit 3,000 teenagers aged 12-17 to test COVID-19 vaccine to evaluate the safety of single dose vaccine, and the results are expected to be announced in 2022.